SIGA Technologies, Inc. (NASDAQ:SIGA) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Phillip Gomez - Chief Executive Officer Dan Luckshire - Chief Financial Officer Conference Call Participants Joaquin Horton - Raymond James Chris Thompson - Hutch Capital Matthew Mark - Jet Capital Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management’ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2020 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaw ...

SIGA Technologies, Inc. (NASDAQ:SIGA) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Phil Gomez – Chief Executive Officer Dan Luckshire – Chief Financial Officer Conference Call Participants Paul Saunders – Hedge Capital Joaquin Horton – Raymond James Teddy Green – Private Investor Andrew Sole – Esopus Creek Matthew Mark – Jet Capital Ralph Weil – R. Weil Investment Management Operator Greetings and welcome to the SIGA Technologies’ Second Quarter 2020 Financial Results Conf ...

WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2020 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 1 ...

SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2020 Earnings Conference Call May 6, 2020 4:30 AM ET Company Participants Phillip L. Gomez - CEO Daniel J. Luckshire - CFO Dennis E. Hruby - Chief Scientific Officer Conference Call Participants Joaquin Horton - Raymond James Paul Saunders - Hedge Capital Unidentified Analyst - Scott Sibley - Equis Group Operator Welcome to the SIGA business update call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal pre ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2020 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware ...

Financial Data and Key Metrics Changes - SIGA's revenue for the year ended December 31, 2019, was approximately $27 million, consisting of about $11 million from the delivery of approximately 36,000 courses of oral TPOXX and approximately $16 million from research and development activities [17] - The company reported a pre-tax operating loss of approximately $2 million and a net loss per diluted share of $0.15 for 2019 [18] - As of December 31, 2019, SIGA had cash and cash equivalents of approximately $161 million, with about $96 million in restricted accounts available for loan-related payments [19] Business Line Data and Key Metrics Changes - The transition from the 1C BARDA contract to the 19C contract was highlighted, with substantial product deliveries and revenues expected to commence in 2020 [16] - The company anticipates delivering approximately 1.66 million courses of TPOXX to the Strategic National Stockpile (SNS) between 2020 and 2024, valued at approximately $532 million [14] Market Data and Key Metrics Changes - The international sales process for oral TPOXX is expected to be slow and unpredictable, with significant time required for government procurement [30][32] - SIGA is pursuing international sales, with a notable contract expected from the Canadian military for up to 15,825 courses of oral TPOXX [34] Company Strategy and Development Direction - The company has authorized a $50 million share repurchase program to signal confidence in its stock value and to create shareholder value [53] - SIGA is exploring new ways to expand its business beyond TPOXX, including collaborations for a second antiviral drug for smallpox treatment and potential acquisitions [54][56] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of preparedness in light of the COVID-19 outbreak and its potential impact on health security [10][12] - The company expects to deliver oral TPOXX courses valued at approximately $101 million to the SNS by April 2021, with deliveries starting in the second quarter of 2020 [21][57] Other Important Information - SIGA has received funding under the 19C contract for the development of a pediatric liquid formulation of TPOXX and for backup manufacturing capabilities [25][26] - The company is preparing a marketing authorization application for the European Medicines Agency (EMA) to expand TPOXX's indications [39] Q&A Session Summary Question: Was the language regarding the 19C contract shown to the customer before publication? - Management indicated that the projections come from the company and that they maintain close contact with customers but do not disclose specific approvals from BARDA [61] Question: How was the $50 million repurchase figure determined? - Management explained that the figure was chosen to signal that the share price is undervalued and to provide flexibility for future investments [64] Question: Concerns about the size of the repurchase relative to cash on hand? - Management acknowledged the concern and emphasized the importance of being disciplined in investment decisions while signaling confidence in the company's future [68]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 Or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 13-38 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2019 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaw ...

PART I - FINANCIAL INFORMATION [Item 1. Condensed Consolidated Financial Statements (Unaudited)](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) The unaudited condensed consolidated financial statements show **$14.4 million** in revenues and a **$1.5 million** net loss for the six months ended June 30, 2019, primarily from TPOXX® sales Condensed Consolidated Balance Sheet Summary (Unaudited) | Account | June 30, 2019 ($) | December 31, 2018 ($) | | :--- | :--- | :--- | | **Total Current Assets** | 121,534,950 | 121,289,845 | | **Total Assets** | 203,092,260 | 203,443,741 | | **Total Current Liabilities** | 11,123,209 | 11,337,405 | | **Total Liabilities** | 99,637,793 | 100,529,054 | | **Total Stockholders' Equity** | 103,454,467 | 102,914,687 | Condensed Consolidated Statements of Operations Summary (Unaudited) | Metric | Three Months Ended June 30, 2019 ($) | Three Months Ended June 30, 2018 ($) | Six Months Ended June 30, 2019 ($) | Six Months Ended June 30, 2018 ($) | | :--- | :--- | :--- | :--- | :--- | | **Total Revenues** | 3,907,611 | 2,661,216 | 14,366,695 | 4,409,150 | | **Operating (Loss) Income** | (1,705,250) | (3,709,691) | 486,704 | (8,244,602) | | **Net and Comprehensive Loss** | (3,162,492) | (7,051,264) | (1,532,715) | (18,633,520) | | **Basic Loss Per Share** | (0.04) | (0.09) | (0.02) | (0.24) | | **Diluted Loss Per Share** | (0.05) | (0.09) | (0.06) | (0.24) | Condensed Consolidated Statements of Cash Flows Summary (Unaudited) | Cash Flow Activity | Six Months Ended June 30, 2019 ($) | Six Months Ended June 30, 2018 ($) | | :--- | :--- | :--- | | **Net Cash Used in Operating Activities** | (4,338,433) | (13,749,616) | | **Net Cash Used in Investing Activities** | (8,948) | (27,863) | | **Net Cash Used in Financing Activities** | (56,590) | (12,328) | | **Net Decrease in Cash** | (4,403,971) | (13,789,807) | | **Cash, Cash Equivalents and Restricted Cash at End of Period** | 175,992,939 | 23,311,779 | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's focus on the health security market with TPOXX®, attributing significant H1 2019 revenue growth to BARDA contract deliveries and noting stable financial condition with **$100.3 million** in cash - The company is a commercial-stage pharmaceutical company focused on the health security market, with its lead product being oral TPOXX®, an antiviral drug for smallpox[96](index=96&type=chunk) - The 2018 BARDA Contract has a potential value of up to approximately **$600.1 million**, including a **$51.7 million** base period, **$23.4 million** in exercised options, and up to **$525.0 million** in unexercised options as of June 30, 2019[97](index=97&type=chunk) Comparison of Results of Operations (Six Months Ended June 30) | Metric | 2019 ($) | 2018 ($) | Change (%) | | :--- | :--- | :--- | :--- | | **Total Revenues** | 14.4 million | 4.4 million | +227% | | - Product Sales | 7.1 million | 0 | N/A | | - R&D Revenues | 7.2 million | 4.4 million | +64% | | **SG&A Expenses** | 6.6 million | 5.9 million | +10% | | **R&D Expenses** | 6.0 million | 6.3 million | -5% | | **Pre-tax Loss** | (2.1 million) | (18.6 million) | -88.7% | - As of June 30, 2019, the company held **$100.3 million** in cash and cash equivalents and **$75.7 million** in restricted cash for Term Loan payments[127](index=127&type=chunk) [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=25&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company faces interest rate risk from its LIBOR-based Term Loan and stock price risk from a liability-classified warrant, with a **0.5% LIBOR increase** raising annual interest by **$0.4 million** - The company is exposed to rising LIBOR rates on its Term Loan, where a **0.5% increase** in the minimum LIBOR rate would raise annual interest payments by approximately **$0.4 million**[138](index=138&type=chunk) - The company is subject to stock price fluctuation risk due to a liability-classified warrant, with every **$1 increase** in SIGA's stock price increasing the intrinsic value of this warrant liability by approximately **$1.5 million**[139](index=139&type=chunk) [Item 4. Controls and Procedures](index=26&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2019, with no material changes in internal control over financial reporting during the quarter - Based on an evaluation as of June 30, 2019, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective[141](index=141&type=chunk) - No changes in internal control over financial reporting occurred during the quarter ended June 30, 2019, that materially affected, or are reasonably likely to materially affect, these controls[142](index=142&type=chunk) PART II - OTHER INFORMATION [Item 1. Legal Proceedings](index=27&type=section&id=Item%201.%20Legal%20Proceedings) The company believes that the resolution of any current legal matters will not materially adversely affect its business or financial condition - The company believes that the resolution of any current pending legal matters will not have a material adverse effect on its business, financial position, results of operations, or cash flow[144](index=144&type=chunk) [Item 1A. Risk Factors](index=27&type=section&id=Item%201A%20Risk%20Factors) This section refers investors to the detailed discussion of risks and uncertainties in the company's 2018 Annual Report on Form 10-K - The company's operations and financial condition are subject to numerous risks and uncertainties which are described in its 2018 Annual Report on Form 10-K[145](index=145&type=chunk) [Item 2. Unregistered Sale of Equity Securities and Use of Proceeds](index=27&type=section&id=Item%202.%20Unregistered%20Sale%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the period - None[146](index=146&type=chunk) [Item 3. Defaults upon Senior Securities](index=27&type=section&id=Item%203.%20Defaults%20upon%20Senior%20Securities) The company reported no defaults upon senior securities during the period - None[147](index=147&type=chunk) [Item 4. Mine Safety Disclosures](index=27&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) No mine safety disclosures were required for the company - No disclosure is required pursuant to this item[148](index=148&type=chunk) [Item 5. Other Information](index=27&type=section&id=Item%205.%20Other%20Information) No other information was required to be disclosed - No disclosure is required pursuant to this item[149](index=149&type=chunk) [Item 6. Exhibits](index=28&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including Sarbanes-Oxley certifications and amendments to key contracts - The exhibits filed include CEO and CFO certifications under Sarbanes-Oxley Sections 302 and 906, amendments to contracts with BARDA, a promotion agreement with Meridian Medical Technologies, Inc., an amendment to the Loan and Security Agreement, and XBRL data files[151](index=151&type=chunk)